<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Clinical Development and Commercialization of CD22-Targeting Chimeric Antigen Receptor (CAR) T-Cell Therapies for Children and Young Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (ALL)</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Clinical Development and Commercialization of CD22-Targeting Chimeric Antigen Receptor (CAR) T-Cell Therapies for Children and Young Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (ALL)</h1>
    <p class="timestamp">Published: 2020-07-30 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is seeking statements of capability and interest from prospective licensees and potential Collaborators interested in participating in collaborative research under a Cooperative Research and Development Agreement (CRADA) to develop autologous CD22 CAR T-cells (m971BBZ lentivirus transduced) for the treatment of B-cell ALL.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2020-16487</p>
    <p><strong>Publication Date:</strong> 2020-07-30</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2020/07/30/2020-16487/clinical-development-and-commercialization-of-cd22-targeting-chimeric-antigen-receptor-car-t-cell">https://www.federalregister.gov/documents/2020/07/30/2020-16487/clinical-development-and-commercialization-of-cd22-targeting-chimeric-antigen-receptor-car-t-cell</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2020-16487</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
